WATERTOWN, Mass.--(BUSINESS WIRE)--Aug. 9, 2006--Acusphere, Inc. (NASDAQ: ACUS) today reported financial results for the quarter ended June 30, 2006 and commented on operational progress. During the three months ended June 30, 2006, the Company’s primary focus remained on its lead product candidate, AI-700, an ultrasound contrast agent being developed for use in echocardiography. The majority of operating expenses were related to the development program for AI-700 which is in Phase 3 clinical trials designed to demonstrate that ultrasound with AI-700 is non-inferior to nuclear stress tests for the assessment of coronary heart disease, the leading cause of death in the United States.
